BPG is committed to discovery and dissemination of knowledge
Featured Articles
11/19/2025 6:18:22 AM | Browse: 133 | Download: 392
 |
Received |
|
2025-04-27 05:39 |
|
Peer-Review Started |
|
2025-04-27 05:39 |
|
First Decision by Editorial Office Director |
|
2025-05-12 04:19 |
|
Return for Revision |
|
2025-05-12 04:19 |
|
Revised |
|
2025-05-26 08:02 |
 |
Publication Fee Transferred |
|
|
|
Second Decision by Editor |
|
2025-08-11 02:52 |
|
Second Decision by Editor-in-Chief |
|
|
|
Final Decision by Editorial Office Director |
|
2025-08-11 13:10 |
|
Articles in Press |
|
2025-08-11 13:10 |
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2025-10-21 09:34 |
|
Publish the Manuscript Online |
|
2025-11-19 05:57 |
| ISSN |
2220-3230 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Health Care Sciences & Services |
| Manuscript Type |
Review |
| Article Title |
Obinutuzumab in kidney transplantation: Past, present, and future
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Evaldo Favi and Marika Morabito |
| Funding Agency and Grant Number |
|
| Corresponding Author |
Evaldo Favi, MD, PhD, Department of General Surgery and Kidney Transplantation, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Via Francesco Sforza No. 28, Milan 20122, Lombardy, Italy. evaldofavi@gmail.com |
| Key Words |
Obinutuzumab; Rituximab; Kidney transplantation; Desensitization; Antibody-mediated rejection; Glomerulopathies; Recurrence; Review |
| Core Tip |
Antibody-mediated rejection and recurrent primary renal diseases remain major causes of kidney transplant loss. Obinutuzumab (OBI) is a type 2 anti-CD20 monoclonal antibody with enhanced peripheral and central B-cell depletion capacities compared to type 1 anti-CD20 monoclonal antibodies. Compared to other B-cell-targeted agents, OBI-induced B-cell depletion is marginally affected by complement function, primarily operating through antibody-dependent cell cytotoxicity, antibody-dependent cell phagocytosis, and direct cell death. These characteristics suggest that OBI might represent a game-changer in the management of highly sensitized transplant candidates, humoral rejection, and relapsing renal diseases. This review summarizes the current knowledge on OBI use in kidney transplantation. |
| Publish Date |
2025-11-19 05:57 |
| Citation |
Favi E, Morabito M. Obinutuzumab in kidney transplantation: Past, present, and future. World J Transplant 2025; 15(4): 108982 |
| URL |
https://www.wjgnet.com/2220-3230/full/v15/i4/108982.htm |
| DOI |
https://dx.doi.org/10.5500/wjt.v15.i4.108982 |
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.
